AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05337774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: The participant will be injected with 5 mCi (185 MBq) \[18F\]PI-2620 via a short line which will be placed in an intravenous line in an antecubital vein. Subjects will be placed in the scanner after injection and dynamic scans will be acquired for 0 to 60 minutes post injection.
Study NCT06645795 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Robot assisted gait training plus conventional physical therapy
Description: Participants will complete 8 weeks of intervention of robot assisted gait training with the ATLAS 2030 exoskeleton (Marsi Bionics) owned by the school which they attend to. They will have 2 weekly sessions (16 sessions in total) for 4 weeks. Each session will last up to 1 hour (depending on the child's tolerance) although a minimum of 30 minutes per session and a minimum of 12 sessions will be set in this time. The training mode will be automatic. In addition, they will continue to carry out the rest of their usual treatments.
Study NCT06645795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pjysical therapy
Description: Participants will complete 8 weeks of conventional therapy, with 2 sessions per week (16 sessions total). During the conventional treatment period, participants will continue with the conventional physical therapy they have received thus far. The content of the usual care treatment does not specifically address gait training, but consists of elements addressing range of motion, tone reduction, balance, activities of daily living, etc. The conventional intervention may be different for each individual based on their needs (to represent usual care), however, participants will be advised not to change the intervention, type, and frequency during the study.
Study NCT06028503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Approximately 3 hours of ACT will be administered based on Gregg et al.;s (2007) protocol:~1. What is ACT?~2. Coping and Stress Management~3. Acceptance and Action
Study NCT06028503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott FreeStyle® Libre® 3
Description: The Abbott FreeStyle® Libre® 3 (FDA approved) consists of a single use disposable electrochemical sensing unit which is placed on the upper arm and an App for smart phones where the participant can view their glucose data, including their current glucose reading, their 'trend arrow' so participants can see how glucose is changing, and their glucose history. The FreeStyle system does not require user calibration. A sensor log will be maintained for accountability of all sensors received as well as used sensors (including the lot/serial number, expiration date, and the date). Sensors will be stored at manufacturers recommendations.
Study NCT06028503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Generic Education
Description: Participants will be given information about how lifestyle choices, including daily dietary choices, affect blood sugar for people with T2D, and best practices related to checking blood sugar and carbohydrate counting if participants are on insulin therapy. These sessions will also include education on diabetes nutrition guidelines and improving self-management through better food and lifestyle choices.
Study NCT06028503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Generic Education
Description: Participants will be given information about how lifestyle choices, including daily dietary choices, affect blood sugar for people with T2D, and best practices related to checking blood sugar and carbohydrate counting if participants are on insulin therapy. These sessions will also include education on diabetes nutrition guidelines and improving self-management through better food and lifestyle choices.
Study NCT06213714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5G Tele-Robotic-Assisted PCI
Description: The 5G Tele-Robotic-Assisted VRS100 system is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
Study NCT05622292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARKIT I-Care Application
Description: HARKIT I-Care Application is an application available in the google play store. The application is specifically developed for the secondary prevention of cardiovascular disease. The features included in the application are (1) Health information logging, (2) Health information education, and (3) Teleconsultation with a cardiologist. Information that can be logged includes smoking behavior, medications, weight, blood sugar level, blood pressure, cholesterol level, physical activity, and Quality of life. Educational content can be accessed by patients in the form of articles and short videos.
Study NCT06176209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: screening tool with biomarkers for prediction of chronic post traumatic neck pain
Description: Diagnostic screening with biomarkers for prediction of chronic post traumatic neck pain
Study NCT04814914 — intervention group
Intervention type: OTHER
Intervention: KB109 + Self Supportive Care
Description: KB109 is a novel glycan
Study NCT04814914 — intervention group
Intervention type: OTHER
Intervention: Self Supportive Care (SSC) Alone
Description: Self Supportive Care (SSC) Alone
Study NCT06571344 — intervention group
Intervention type: DRUG
Intervention: Cholecalciferol
Description: The patients with vitamin D (25(OH)D) levels \< 30 ng/mL, and 30-50 ng/ml will recieve a dose of cholecalciferol at 70,000 IU per week (20,000 IU + 20,000 IU + 30,000 IU per week).~In the patients with 25(OH)D levels 50-80 ng/mL the dose of cholecalciferol will be adjusted to avoid exceeding the upper limit of the laboratory norm.
Study NCT05117996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: capsule endoscopy
Description: capsule endoscopy
Study NCT05117996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: capsule endoscopy
Description: capsule endoscopy
Study NCT05117996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard small bowel preparation
Description: 2 L of polyethylene glycol and free residue diet the day before the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
Study NCT05117996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified small bowel preparation
Description: Liquid diet the evening before and water on the morning of the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
Study NCT05895994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD13-02 cell infusion
Description: CAR-T cells
Study NCT05384210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: Milnacipran will be administered according to the treatment recommendations for fibromyalgia, starting with 50 mg once daily for 1 week then increasing to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 months.
Study NCT05384210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Patients will receive gabapentin (1200 mg twice daily) as a monotherapy. Gabapentin will be administered according to the treatment recommendations for FM patients starting with 400 mg 3 times per day, then increasing the dose to 800 mg 3 times per day with a maximum dose of 2400 mg per day according to efficacy and tolerability for 3 months
Study NCT05384210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined gabapentin/milnacipran
Description: Patients will receive combined gabapentin as group B and MLN as group A
Study NCT05076799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 ml lactulose combined with 1 L PEG
Description: the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
Study NCT05076799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 ml lactulose combined with 2 L PEG
Description: the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
Study NCT05076799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 ml lactulose
Description: the participants were instructed to consume 200 ml lactulose alone
Study NCT05076799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 L Polyethylene glycol solution
Description: the participants were instructed to consume 3000 mL of PEG solution
Study NCT05233007 — intervention group
Intervention type: PROCEDURE
Intervention: Minor endoscopic biopsy
Description: As per standard of care
Study NCT05302570 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Proton Beam Therapy
Description: 5 fractions of 5 Gy of PBT to clinical tumor volume +/- an additional simultaneous 1 Gy per fraction to any pre-determined at-risk margin (for a total of 6 Gy per fraction x 5 fractions for at-risk margins as a simultaneous integrated boost (SIB)).
Study NCT05009966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYSA1801 for injection
Description: SYSA1801 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT06359860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-1898 tablets
Description: Supplied as 5 mg and 40 mg tablets
Study NCT04158349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 0 (85 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.
Study NCT04158349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRI
Description: mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.
Study NCT05081570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telecare consultation
Description: Two tertiary stroke care consultations will be provided by stroke nurses via telecare in 2 months. Consultation content includes provide education on modifying stroke-specific risk factors, disseminate self-management knowledge, reinforce the importance of medication compliance, revise the blood and investigation results, and co-design and follow-up on mutually agreed rehabilitation goals with the subjects. When necessary, the nurse will also refer the stroke survivors to multidisciplinary team members according to the referral guidelines. The nurse will also encourage the patients' family and/or informal caregivers to participate in the consultations.
Study NCT06187246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar-based intervention
Description: Intervention was aimed at improving sexual variables (sexual satisfaction, sexual function, and initiative and sexual communication), and variables that are known to affect orgasm consecution (sexual self-esteem, sex-guilt, and sexual anxiety). To achieve this objective, it focused on fostering participants' abilities to increase their levels of sexual stimulation, and the engagement in personal values, along with identifying and modifying dysfunctional thoughts about sexuality. The techniques used included psychosexual education, cognitive restructuring, virtual exposure, sexual stimulation, and engagement in personal values from the acceptance and commitment therapy (ACT) perspective.~It was delivered via a metaverse: Second Life.
Study NCT06187246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual informative talks
Description: Participants were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure). Participants received three individual sessions once a month, and had a duration of one hour.
Study NCT03771612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)
Study NCT03771612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Half of the participants will be randomly assigned to receive a placebo pill twice daily
Study NCT05487313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: fascial plane injection guided by fluoroscopic device after ultrasound guidance
Study NCT05674500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Training on standardized coaching language
Description: The faculty trainer participants in training groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The training video will demonstrate the use of recommended coaching language for endoscopy instruction (e.g., recommended 14 standard terms, need to refer to the screen when directing a trainee as opposed to their hands, use of a clockface analogy) and communication best practices (e.g., checking to ensure understanding, avoidance of cognitive overload, task deconstruction).
Study NCT05767294 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: clinical manifestation (body temperature, fever days before admission, cough, red throat/sore throat, runny nose, shortness of breath, wheezing, vomiting), physical signs (auscultation of lungs, X-ray results), length of stay, therapeutic measures (oxygen therapy, ICU admission, antibiotic therapy, etc.)
Study NCT06182904 — intervention group
Intervention type: DEVICE
Intervention: Dynamic compression plate
Description: Fixation of fibula in some cases with dynamic compression plate
Study NCT06164028 — intervention group
Intervention type: OTHER
Intervention: cognitive interview
Description: Participants will take part in a semi-structured qualitative interview (\~1 hour).
Study NCT05335213 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA gene sequencing
Description: DNA extraction and 16S rRNA gene sequencing DNA extraction, 16S rRNA gene amplification, and deep sequencing of the 16S rRNA amplicon performe.~The V4-V5 region of the 16S rRNA gene amplify with barcodes for multiplexing.
Study NCT06094049 — intervention group
Intervention type: OTHER
Intervention: Preference test group
Description: Standard meals will be prepared including the commonly consumed porridge and/or bread using flour fortified with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food.
Study NCT06094049 — intervention group
Intervention type: OTHER
Intervention: Triangle test group
Description: Standard meals will be prepared including the commonly consumed porridge and/or bread using unfortified flour and fortified-flour with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food and who will be blinded to the flour type.
Study NCT04732260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Each patient will receive 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP.~5 women will receive 240 mg. 5 women will receive 480 mg.
Study NCT06075069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feeding appliance
Description: A preliminary alginate impression was made using wax stock tray to get a preliminary cast and construct a self-cure acrylic custom-made tray. A Medium viscosity rubber base impression material was used for making final impression which in turn will be poured to obtain a master cast. On this master cast, a feeding appliance will be constructed. Readymade facebow with two straight side length of hard, rounded, of 2mm diameter, 15cm length Nickel-Chrome wire with omega loops (at the end of the wire) was used to form extra-oral wings to be used as a retentive aid to maintain the prosthesis in situ. The appliance was fabricated in clear acrylic resin then finished and polished. A small piece of cold cure acrylic resin was added and adapted to the omega loops and manipulated to follow the checks contour.
Study NCT05562505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Venovenous ECMO
Description: ECMO therapy for patients with hypoxic respiratory failure.
Study NCT05213481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received Tepotinib hydrochloride hydrate film-coated tablet once daily with food on Day 1 and Day 26 in the morning.
Study NCT05213481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Carbamazepine 100 mg twice daily at Day 8 and 9, 200 mg twice daily at Day 10 and 11, 300 mg twice daily from Day 12 to 32.
Study NCT06220773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019A
Description: Subjects take the investigational products once a day for 12 weeks.
Study NCT06220773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1019A
Description: Subjects take the investigational products once a day for 12 weeks.
Study NCT06220773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019B
Description: Subjects take the investigational products once a day for 12 weeks.
Study NCT06220773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BR1019B
Description: Subjects take the investigational products once a day for 12 weeks.
Study NCT06220773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1019B
Description: Subjects take the investigational products once a day for 12 weeks.
Study NCT06220773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BR1019C
Description: Subjects take the investigational products once a day for 12 weeks.
Study NCT06220773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BR1019A-1
Description: Subjects take the investigational products once a day for 12 weeks.
Study NCT06220773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1019A-1
Description: Subjects take the investigational products once a day for 12 weeks.
Study NCT06220773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1019B-1
Description: Subjects take the investigational products once a day for 12 weeks.
Study NCT06220773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019C-1
Description: Subjects take the investigational products once a day for 12 weeks.
Study NCT06220773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1019C-1
Description: Subjects take the investigational products once a day for 12 weeks.
Study NCT05674500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Training on goal setting
Description: The faculty trainer participants in the control groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The video will be a 'dummy' colonoscopy training video which outlines how to set goals ahead of an endoscopy training session. The video will not discuss standardized coaching language and/or communication best practices.
Study NCT05284435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Email (iCBT-E)
Description: Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails, therapists will serve to provide encouragement and support as the parent works through the program independently.
Study NCT05284435 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy-Email and Videoconferencing (iCBT-EV)
Description: Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails and six videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently. Therapists will also assist the parent with any problem-solving as needed.
Study NCT06427525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application-based adolecent obesity education
Description: Mobile application-based adolecent obesity education
Study NCT05431647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensory integration therapy
Description: The individuals were divided into two as randomized controlled. Both physiotherapy and sensory integration therapy were applied to the intervention group. Each treatment was applied as 2 sessions per week, 2 days a week for 8 weeks. In the control group, only physiotherapy treatment was applied for 8 weeks, 2 days a week, 2 sessions per week.